|
Effective immediately, NRG-LU002, Maintenance Systemic Therapy Versus Local Consolidative Therapy (LCT) Plus Maintenance Systemic Therapy for Limited Metastatic Non-Small Cell Lung Cancer (NSCLC) A Randomized Phase II/III Trial, is permanently closed to accrual. As broadcasted on November 12, 2021, NRG-LU002 was temporarily closed to accrual for a protocol-specified analysis for the phase II portion of the study. NRG-LU002 will not move to the phase III portion of the study, because the phase II progression-free survival analysis did not meet the protocol-specified criterion. Data collection to complete the phase II study objectives will continue per protocol. Results from the phase II analysis will be presented at an upcoming scientific meeting.
Reminders:
- Protocol Amendment 11 (version date October 18, 2023) was released to sites on November 7, 2023; please continue to process.
- Data collection and site IRB renewal for closed studies must continue until the study is terminated.
| 
